| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font
First page > Show document

Show document Help

Title:Biooznačevalci za napoved odziva na vedolizumab pri bolnikih s kronično vnetno črevesno boleznijo : diplomsko delo univerzitetnega študijskega programa I. stopnje
Authors:ID Metlika, Lara (Author)
ID Potočnik, Uroš (Mentor) More about this mentor... New window
ID Gole, Boris (Comentor)
Files:.pdf UN_Metlika_Lara_2020.pdf (1,20 MB)
MD5: C7F1554EB1BB3F356DBD7A1B360CDC67
PID: 20.500.12556/dkum/2f20ba61-ddc7-4cbd-9dc7-120b30429aff
 
Language:Slovenian
Work type:Bachelor thesis/paper
Typology:2.11 - Undergraduate Thesis
Organization:FKKT - Faculty of Chemistry and Chemical Engineering
Abstract:Eno izmed obetavnejših bioloških zdravil za zdravljenje kronične vnetne bolezni je biološko zdravilo vedolizumab. Na žalost je neodziv na terapijo še vedno prisoten pri 1/3 bolnikov. Natančna napoved odzivnosti pred začetkom terapije bi bila zato zelo pomembna. V diplomskem delu je prikazan sistematski pregled literature. Iskanje PubMed je bilo izvedeno z vnaprej določenimi ključnimi besedami in izrazi, da se ugotovijo ustrezne študije o napovedovalcih odziva. V rezultatih so prikazani dobljeni tipi markerjev; proteinski, klinični, v povezavi z koncentracijo ter na ravni mRNA, ter medsebojne primerjave različnih vrednosti. Bolniki s hudo boleznijo ali predhodno izpostavljenostjo anti-TNF terapiji se manj verjetno odzovejo na vedolizumab. Prav tako so zanimivi proteinski markerji C-reaktiven protein, raven albumina ter fekalnega kalprotektina. Zaključimo, da je v prihodnje potrebnih še več študij ter bolj sistematičen pristop k iskanju biomarkerjev.
Keywords:kronična vnetna črevesna bolezen, Crohnova bolezen, ulcerozni kolitis, vedolizumab, odziv, in napovedovalci odziva
Place of publishing:Maribor
Place of performance:Maribor
Publisher:[L. Metlika]
Year of publishing:2020
Number of pages:X, 43 str.
PID:20.500.12556/DKUM-77382 New window
UDC:615.015.1:616.34-002(043.2)
COBISS.SI-ID:33448451 New window
NUK URN:URN:SI:UM:DK:WGP3EH5S
Publication date in DKUM:13.10.2020
Views:1784
Downloads:98
Metadata:XML DC-XML DC-RDF
Categories:KTFMB - FKKT
:
METLIKA, Lara, 2020, Biooznačevalci za napoved odziva na vedolizumab pri bolnikih s kronično vnetno črevesno boleznijo : diplomsko delo univerzitetnega študijskega programa I. stopnje [online]. Bachelor’s thesis. Maribor : L. Metlika. [Accessed 8 April 2025]. Retrieved from: https://dk.um.si/IzpisGradiva.php?lang=eng&id=77382
Copy citation
  
Average score:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:28.08.2020

Secondary language

Language:English
Title:Biomarkers of response to vedolizumab in inflammatory bowel diseases patients
Abstract:Vedolizumab represents one of the most promising biological medications used in the chronic inflammatory disease treatment. Unfortunately, 1/3 of the patients are still classified as non-responsive to the vedolizumab therapy. Therefore, it would be extremely important to determine the precise level of responsiveness before starting the therapy. The present diploma thesis examines a systematic literature review. PubMed search was carried out by means of the pre-defined key words and expressions in order to establish the relevant studies on predictors of response. The results show the types of markers obtained in various studies: protein markers, clinical markers, markers related to the vedolizumab concentration, and markers on mRNA level. The results also illustrate the comparison between different marker values which were given in different scientific articles. Patients with mild form of the disease and anti-TNF naive patients are more likely to respond to the vedolizumab therapy. The following protein markers have also proved to be very interesting: C-reactive protein as well as the levels of albumin and faecal calprotectin. In the end it can be concluded that further research as well as a more systematic approach to finding biomarkers are needed in the future.
Keywords:Chronic inflammatory bowel disease, Crohn's disease, ulcerative colitis, vedolizumab, response, and predictors of response.


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica